Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...
On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback